Tailoring Antiplatelet Therapy in PCI

Slides:

Advertisements

Similar presentations

Khawar Kazmi. Thrombosis LipidsInflammation Thrombus Platelets and thrombin Quiescent Plaque Plaque rupture PATHOGENESIS ACUTE CORONARY SYNDROME.

Advertisements

Pharmacology in Acute Coronary Syndromes: Anti-platelet Agents Tim Kinnaird, University Hospital Wales, Cardiff and Vale NHS Trust.

Novel antithrombotic agents in acute coronary syndromes: better or worse than P2Y12 inhibitors Giuseppe Biondi Zoccai Sapienza Università di Roma

1 Update on antiplatelet and anticoagulant drugs: sticky stuff KFJ Ng May 2011.

Pocket Guide to Anticoagulation in AF & Dual Antiplatelet Therapy in ACS Rumi Jaumdally 2015 This brief presentation will summarise the recently published.

The Leeds Teaching Hospitals NHS Trust PHARMACOLOGY IN ACS OVERVIEW OF THE DATA : PRACTICAL ADVICE JIM McLENACHAN, LEEDS. 25 th January, 2007.

Trial Vignettes Cameron G Densem TRITON-TIMI 38 ARMYDA OPTIMA.

The Effect of Cangrelor and Access Site on Ischemic and Bleeding Events – Insights from CHAMPION PHOENIX J. Antonio Gutierrez, MD, MHS, Robert A. Harrington,

수요저널 우종신. ACC/AHA Guideline Focused Update 2011 Class I 1. After PCI, use of aspirin should be continued indefinitely. (Level of Evidence.

_________________ Caitlin M. Gibson, PharmD, BCPS

Heparin Should be the First-line Therapy for Patients with ACS/AMI

The American College of Cardiology Presented by Dr. Adnan Kastrati

When should we start a P2Y12 inhibitor in patients with an acute coronary syndrome? G. Montalescot Dr. Montalescot reports research Grants to the Institution.

Should We Preload STEMI Patients with Antiplatelet Therapy?

Antiplatelet Therapy For STEMI: The Case for Cangrelor

Learning Objectives. Learning Objectives Variable Response to Clopidogrel.

Preventing Thrombotic Complications in ACS: State of the Art

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons From Clinical Trials.

New Concepts in Peripheral Artery Disease: Emerging Role of Antithrombotics.

Atrial Fibrillation and PCI

Anticoagulants in Interventional Cardiology:

Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.

Know Your ABCs: Antiplatelet Therapy, Benefits/Bleeding, and Cardiac Surgery State of the Art: The Role of Antiplatelet Therapy in the Cardiac Surgical.

Glenn N. Levine et al. JACC 2016;68:

Achieving Long-Term Protection Post-MI

Gilles Montalescot, ACTION Study Group, Paris

Emerging Data on ACS Management From ACC

Applying New Data in Practice:

PAD Patients vs Post-ACS Patients:

Figure 3 Metabolism pathway of antiplatelet agents

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.

Introduction Antiplatelet Agents ADP Receptor Antagonists.

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

Advances in Dyslipidemia: What Have We Learned From ACC 2017

Nat. Rev. Cardiol. doi: /nrcardio

Antithrombotics and PAD: A New Paradigm in Practice

New Perspectives in CAD and PAD: Weighing the Latest Evidence

What Has Been Tried and What Is True?

Selecting NOACs for High-Risk Patients

Antiplatelet Therapy and Secondary Prevention

Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI

Panelists. Secondary Prevention of Acute Ischemic Stroke: Can We Improve Outcomes?

Tailoring Hemophilia Prophylaxis Therapy

Learning Objectives PLATO Primary Efficacy End Point CV Death, MI, or Stroke.

A Unified Approach to Anticoagulant Therapy in ACS: What's Missing?

AF and PCI in Practice.

Comparison of US and European Guidelines Oral Antiplatelet Therapy in Primary PCI/STEMI.

Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.

The Management of ACS “Updated Perspectives and Goals” Rafid F. Al-Aqeedi FIBMS ( Med ), MRCP (London), DM ( Int.Card.), FACC, FESC Consultant Interventional.

Thank you for taking the pre-assessment

Section F: Clinical guidelines

New LDL-C Lipid Targets

Overview. Complex Cases in PCI: Tailoring Antiplatelet Therapy to Improve Outcomes.

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

Duration of Dual Antiplatelet Therapy

Factor Xa Inhibitors in PAD

Oral Prostacyclin Pathway Agents in PAH

What oral antiplatelet therapy would you choose?

LDL Cholesterol.

The Challenge of AF and PCI: Practical Strategies to Improve Outcomes

Factor Xa Inhibitors in Coronary Artery Disease

Improving Adherence to Antiplatelet Therapy After an ACS Event

Cardiology Fellow X Factor: An ACS Case of Therapeutic Challenges

Roberta Rossini et al. JCIN 2018;11:

ESC Guideline on the Management of STEMI Recommendation for DAPT

Figure 3. Trials and possible strategies for un-guided and guided DAPT de-escalation. The figure shows studies and strategies on DAPT de-escalation approaches.

PCSK9 Inhibitors and Real-World Evidence

Antithrombotic Therapy in AF Patients Undergoing PCI

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Presentation transcript:

Tailoring Antiplatelet Therapy in PCI

Program Goals

Antiplatelet Options for PCI

Pre-Cath Antiplatelet Treatment 2014 AHA/ACC NSTE-ACS Recommendations

Clopidogrel Pretreatment

ACCOAST Major Efficacy and Bleeding Endpoints

Goal of Pretreatment

CURE

2014 ACC/AHA Guideline Recommendations Early Invasive and Ischemia-Guided Strategies

Not All Platelet Inhibition Is the Same

Case

PLATO Efficacy and Bleeding Endpoints

Case (cont)

2014 ACC/AHA Guideline Recommendations

Case 2

Case 2 (cont)

Case 2 (cont) Angiogram Findings

Cangrelor The CHAMPION PHOENIX Trial

Crushed Ticagrelor vs Cangrelor

Mechanism of Action: P2Y12 Agents

Decisions Guiding Long-Term Continuation of DAPT

Predicting Benefit and Harm of DAPT Beyond 1 Year After PCI

Platelet Function Testing, Genetic Testing, and Switching of P2Y12 Inhibitors

Platelet Function Testing Potential Uses

Abbreviations

Abbreviations (cont)